Showing 3101-3110 of 6040 results for "".
Preparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Busy by Design Plans: How to Use Downtime to Drive Revenue and Make Uptime Smoother for Your Team
https://practicaldermatology.com/issues/september-2025/busy-by-design-plans-how-to-use-downtime-to-drive-revenue-and-make-uptime-smoother-for-your-team/37641/In today’s fast-paced dermatology industry, treatments can sometimes feel more transactional than transformational.Dr. DiAnne Davis on Mentorship, Lasers, Skin of Color, and More
https://practicaldermatology.com/issues/september-2025/dr-dianne-davis-on-mentorship-lasers-skin-of-color-and-more/37643/In a recent YoungMD Connect virtual mentorship session, DiAnne Davis, MD, FAAD, a dermatologist based in Dallas, discussed her journey from patient to dermatologist, the influence of mentorship, and her commitment to advancing safe, effective cosmetic procedures for patients with skin of color.Comorbidities in Alopecia Areata
https://practicaldermatology.com/issues/july-2025/comorbidities-in-alopecia-areata/36507/Alopecia areata (AA) is a chronic, relapsing immune-mediated disorder that causes nonscarring hair loss that can significantly impact a patient’s quality of life.The View from Under the Hood
https://practicaldermatology.com/issues/january-february-2025/the-view-from-under-the-hood/32967/As 2025 brings new approvals for treatments for hidradenitis suppurativa, chronic spontaneous urticaria, psoriatic arthritis, and several other diseases that need answers, this is a good time for us to remember that the most important approach to treatment starts with the right diagnosis.Journal Club: Biologics for Young Children
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-biologics-for-young-children/32400/Practical Dermatology Editorial Board member Lawrence Eichenfield, MD, FAAD, Dawn Eichenfield, MD, PhD, discuss the article "Biologic therapies in infants and children younger than 6 years of age with atopic dermatitis: suitability and practical considerations," from Expert Opinion on Drug Safety. RJournal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national databaseDeveloping Core Outcome Sets: The Importance of Common Standards for Clinical Studies of Specific Diseases and Conditions
https://practicaldermatology.com/topics/feature/developing-core-outcome-sets-importance-common-standards-clinical-studies-specific-diseases-and-conditions/26654/Developing Core Outcome Sets: The Importance of Common Standards for Clinical Studies of Specific Diseases and ConditionsEmbrace Your Curiosity: The Power of Questions
https://practicaldermatology.com/topics/practice-management/embrace-your-curiosity-the-power-of-questions/24031/Asking empowering questions may yield more creative answers.Lead from Ahead (For a Change)
https://practicaldermatology.com/topics/practice-management/lead-from-ahead-for-a-change/23973/